Give it a few days while the results are gone over I reckon.
This result seems to outperform the competition drug by a good margin. Dont think that could have been priced in. Too much unknown.
I am thinking the basket trial wasnt fully understood by retail. And disapointment towards low overal response rate perhaps. The expansion trial into the target cancer will fix that. Competitor drug had 36% response rate for target cancer. PTX 100 has already done better than that, but small cohort.
Ann: PTX-100 trial advances following successful Phase 1b, page-68
-
- There are more pages in this discussion • 339 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
